These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29736895)

  • 1. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.
    McQueen RB; Sheehan DN; Whittington MD; van Boven JFM; Campbell JD
    Pharmacoeconomics; 2018 Aug; 36(8):957-971. PubMed ID: 29736895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
    Faria R; McKenna C; Palmer S
    Value Health; 2014 Dec; 17(8):772-82. PubMed ID: 25498772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.
    Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    Pharmacoeconomics; 2018 Oct; 36(10):1165-1200. PubMed ID: 29869050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
    García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
    Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?
    Kim CH; Dilokthornsakul P; Campbell JD; van Boven JFM
    J Allergy Clin Immunol Pract; 2018; 6(2):619-632. PubMed ID: 28967548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of asthma therapy: a comprehensive review.
    Domínguez-Ortega J; Phillips-Anglés E; Barranco P; Quirce S
    J Asthma; 2015; 52(6):529-37. PubMed ID: 25539023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
    Brown R; Turk F; Dale P; Bousquet J
    Allergy; 2007 Feb; 62(2):149-53. PubMed ID: 17298423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.
    Zhou H; Lu Y; Wu B; Che D
    J Asthma; 2020 Jan; 57(1):87-94. PubMed ID: 30507328
    [No Abstract]   [Full Text] [Related]  

  • 10. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain.
    Vennera Mdel C; Valero A; Uría E; Forné C; Picado C
    Clin Drug Investig; 2016 Jul; 36(7):567-78. PubMed ID: 27142072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
    Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
    J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence.
    Igarashi A; Kaur H; Choubey A; Popli A; Muthukumar M; Yoshisue H; Funakubo M; Ohta K
    Value Health Reg Issues; 2022; 27():41-48. PubMed ID: 34784547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions.
    Ehteshami-Afshar S; Zafari Z; Hamidi N; FitzGerald JM; Lynd L; Sadatsafavi M
    Value Health; 2019 Sep; 22(9):1070-1082. PubMed ID: 31511184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice.
    Martínez-Moragón E; Climent M; Chiner E; Fernández-Aracil C; Sánchez-Toril F; Lluch-Tortajada I
    Farm Hosp; 2019 May; 43(3):101-109. PubMed ID: 31072288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic review of medical management of persistent asthma.
    Cheng JW; Arnold RJ
    Allergy Asthma Proc; 2008; 29(2):109-22. PubMed ID: 18430307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review.
    Chongmelaxme B; Chaiyakunapruk N; Dilokthornsakul P
    J Med Econ; 2019 Jun; 22(6):554-566. PubMed ID: 30663455
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.